Angiotech Pharmaceuticals (ANP.TO) Buy, Sell…

Angiotech Pharmaceuticals (ANP.TO)

0.00

-0.00 (0.00%)

2 watching

DON'T BUY

Biotech stocks have not done well for quite awhile. Great company, but the market does not appreciate what they have in their pipeline. Big problem is that all their revenues are from stents via Boston who are having a number of recalls. Made a number of acquisitions in the last few years and expect they will start bearing fruit soon. Good management.

DON'T BUY

Coming out with other products is going to be their big task down the road. Hit and miss right now.

PAST TOP PICK

(A Top Pick Nov 9/05. Up 4%.) When he picked these stocks, he was trying to play the Christmas bounce. All 3 failed to materialise. This is still in the basing period and has not broken out yet.

DON'T BUY

Manufactures coated stents. In competition with Johnson & Johnson (JNJ-N). A one trick pony. Boston Scientific (BSX-N) is a better way to play this.

TRADE

He believes the sector is good, but has no position on this stock.

WATCH

Just acquired American Medical Instruments. This is a very positive move which gives them the ability to grow. They'll have to do more of this to get the stock moving.

DON'T BUY

Boston Scientific (BSX-N) is buying Guidant (GDT-N) which is a competitor of Angiotech. This is very negative for Angiotech. This company has been a one-hit wonder.

TOP PICK

(A Top Pick July 4/05. Down 5%.) It is hard trying to read companies in the health care sector, but this one has had a long base with a lot of series of lows which seems to be that it is getting ready for a pop. All his picks are for a seasonal Santa Claus rally trade. If they move 20%, say thank you and get the heck out.

BUY

Trading at around 13 X earnings which is cheap for a company that is growing. Market has given them a lot of credit for their coated stent, but is worried about competion and with them owning 75% of the market are not sure they can hold this. At a very cheap level now. Has bought it, and will continue to hold.

DON'T BUY

Using a 5 year chart as he wants to look at as it is coming back to multi-year support level. The trend is still bearish and there is no sign of it ending. Getting close to long term support and from that perspective it gets interesting. You need to see positive price action and some volume coming in.

BUY

Angiotech and Boston Scientific (BSX-N) are up against Johnson & Johnson (JNJ-N) which is like being in the ring with a heavyweight. Lost ground when they had their product recalled. Still a good company.

DON'T BUY

The medical device group is performing fairly well. The problem this company is having is that it is really a one product company which is a risk. Competition Johnson and Johnson (JNJ-N) has a product which is perceived to be safer so market share has dropped.

WEAK BUY

Had some rough patches lately. Biggest claim to fame is licensing of their technology to Boston Scientific. They continue to be successful, the problem is, what do they do for an encore. Sales are set to decline. Have a good cash position and hopefully they will come up with a new product that will be successful. High risk and potentially high reward.

BUY

Continues to like this stock. Their stents, sold through Boston Scientific (BSX-N) is gaining market share over Johnson & Johnson (JNJ-N). A world class Canadian winner.

TOP PICK

The biotech sector of the TSX is absolutely the worst sector of the past couple of years. This one is a highly speculative pick. Can see a descending wedge on the chart which is a bullish sign. Watch for the breakout to the upside.

Showing 31 to 45 of 140 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Angiotech Pharmaceuticals (ANP.TO)